Section 2 of 6
Executive summary
8 evidence topics · 27 sources
Clinical benefits of Inaxaplin
Burden of APOL1-mediated kidney disease
Summary: population, risk, and disease course
APOL1-mediated kidney disease (AMKD) occurs in people with two APOL1 risk variants (G1 and G2) and affects people of African ancestry. Approximately 13% of Black individuals in the US, “more than 5 million people”, have a high-risk APOL1 genotype. Penetrance is incomplete: approximately 15% to 20% of African American individuals with two risk alleles develop CKD, and the lifetime risk of ESKD has been estimated at 15% to 30%. A Delphi consensus panel estimated that “up to 3% of the Black population will be affected”. Vertex estimates that AMKD affects approximately 150,000 people in the U.S. and Europe; no peer-reviewed count of people with AMKD in the U.S. or Europe was identified.
In the Atherosclerosis Risk in Communities study, carrying two risk alleles was associated with a 1.88-fold increased risk of ESRD compared with zero or one risk allele. A Vertex-sponsored testing page states that AMKD patients “progress to dialysis nine to 12 years earlier” than CKD patients of African ancestry with zero or one risk variant. In 2023, kidney failure was over four times more common among Black people than among White people in the United States.
Summary: economic burden and current treatment
No cost or resource-use study specific to AMKD was identified. In the United States, total Medicare costs for people with ESRD reached $55.3 billion in 2023, and the yearly cost per person with fee-for-service coverage and CKD was $31,176 in 2023. No therapy directed at AMKD is approved; the KDIGO 2025 controversies conference report states that there are “no established treatments or treatment recommendations for APOL1 kidney disease”. KDIGO guidelines recommend RAS blockade, blood pressure control, and dietary salt restriction for adults with FSGS, and an SGLT2 inhibitor for adults with CKD who meet the criteria the guideline specifies. In AASK, APOL1 status did not interact with the randomized blood-pressure goal or antihypertensive drug. In a real-world cohort of 1,332 people with AMKD, 45.7% had CKD stage 4 or 5, 35.7% had a RAAS inhibitor fill or administration, and 10.5% had an SGLT2 inhibitor fill or administration.
Inaxaplin efficacy and safety
Summary: regulatory status and pivotal trial
Inaxaplin (VX-147) is an investigational oral small-molecule inhibitor of APOL1 channel function developed by Vertex Pharmaceuticals. It has FDA Breakthrough Therapy designation and EMA PRIME designation. AMPLITUDE (NCT05312879) is an adaptive phase 2/3, randomized, double-blind, placebo-controlled trial in participants aged 10 to 65 years with two APOL1 variants, a UPCR of 0.7 to less than 10 g/g, and an eGFR of 25 to less than 75 mL/min/1.73 m2; the registry record shows 522 participants enrolled, and its phase 3 portion compares inaxaplin 45 mg once daily with placebo on top of standard of care. Vertex states that it will conduct the pre-planned interim analysis “for potential U.S. accelerated approval” after the interim analysis cohort reaches 48 weeks of treatment and share the data in early 2027. As of November 2026, no AMPLITUDE efficacy or safety results have been reported.
Summary: phase 2a study VX19-147-101
In the single-group, open-label phase 2a study, 16 participants with biopsy-proven FSGS and two APOL1 variants received inaxaplin for 13 weeks (15 mg once daily for 2 weeks, then 45 mg once daily for 11 weeks) with standard care. Among the 13 participants who met the adherence threshold, the mean change from baseline in UPCR at week 13 was -47.6% (95% CI, -60.0 to -31.3); in all 16 participants, it was -44.0% (95% CI, -56.3 to -28.3), and 1 participant had no reduction. Of the 16 participants, 15 (94%) had at least one adverse event, all mild or moderate, with no discontinuations due to adverse events. Headache (4 participants, 25%), back pain (3, 19%), and nausea (3, 19%) were the most frequent events, and 1 participant had two serious adverse events (deep-vein thrombosis and uterine leiomyoma) that the investigator considered unrelated to inaxaplin.
Summary: phase 2 study AMPLIFIED
AMPLIFIED (NCT06794996) was a single-arm, open-label study of inaxaplin 45 mg once daily added to optimized standard of care in 41 participants: cohort 1 (AMKD with modest proteinuria, n=23) and cohort 2 (AMKD with type 2 diabetes, n=18). At week 13, the geometric mean percent change in UACR was -42.7% (95% CI -58.3%, -21.1%) in cohort 1 and -17.3% (95% CI -36.3%, 7.2%) in cohort 2, and UPCR decreased by 44.7% and 25.4%, respectively; the confidence intervals were generated post hoc. No serious adverse events related to inaxaplin occurred, all adverse events were mild or moderate, headache was the most common adverse event (7.3%), and 5 participants had isolated, asymptomatic transaminase elevations that resolved.
Summary: phase 1 and clinical pharmacology studies
In two phase 1 studies in healthy adults (VX18-147-001 and VX20-147-008), 134 participants received inaxaplin and 44 received placebo. Adverse events occurred in 33 participants receiving inaxaplin (24.6%) and 10 receiving placebo (22.7%); all were mild or moderate, there were no serious adverse events, and headache occurred in 10.4% of participants receiving inaxaplin and 2.3% receiving placebo. No participant had a QTcF interval above 480 msec. In single-dose studies of 45 mg, the geometric least squares mean ratio of exposure was reported as below 120% in severe renal impairment and below 125% in mild or moderate hepatic impairment, and one participant with a Child-Pugh score of 9 had an AUC about 2.2-fold higher than participants with scores of 7 or below.
Budget impact of Inaxaplin
Summary: price, economic evaluations, and forecasts
Inaxaplin has no announced price, and no published cost-effectiveness analysis, budget impact model, health technology assessment, or ICER review of inaxaplin or of any other APOL1-targeted therapy was identified. A 2025 narrative review states that the cost-effectiveness of emerging APOL1-targeted therapies “remains uncertain”. A GlobalData forecast published in 2024 projects U.S. inaxaplin revenue of $138 million in 2034. Vertex estimates that AMKD affects approximately 150,000 people in the U.S. and Europe, and Fierce Biotech reported that an FDA label covering the two AMPLIFIED cohorts would add about 100,000 people to the target population. Use of inaxaplin would require APOL1 genotyping; Vertex sponsors APOL1 genetic testing at no cost to eligible patients through Labcorp, Natera, and Arkana Laboratories, and no public list price or Medicare payment rate for APOL1 genotyping was identified.
Conclusions
Summary
Inaxaplin is an investigational oral APOL1 channel inhibitor for a genetically defined kidney disease for which no targeted therapy is approved. The efficacy evidence available as of November 2026 consists of proteinuria reductions in two open-label, single-arm studies: a mean UPCR change of -47.6% at week 13 in 13 participants with FSGS, and UACR changes of -42.7% and -17.3% at week 13 in the two AMPLIFIED cohorts (analyses of 18 and 14 participants with a week 13 assessment). Reported adverse events were mild or moderate, with headache the most frequent across studies. No randomized efficacy or safety results are available; the AMPLITUDE interim analysis, which Vertex states could support potential U.S. accelerated approval, is expected in early 2027, and the final analysis uses eGFR slope. Inaxaplin has no announced price, no economic evaluation has been published, and treatment would require APOL1 genotyping to identify eligible people.